Ministry of Education, Culture, Sports and Technology of Japan Gastric cancer in young adults has been pointed out to comprise a subgroup associated with distinctive clinicopathological features, including an equal gender distribution, advanced disease, and diffuse-type histology. Comprehensive molecular analyses of gastric cancers have led to molecular-based classifications and to specific and effective treatment options. The molecular traits of gastric cancers in young adults await investigations, which should provide a clue to explore therapeutic strategies. Here, we studied 146 gastric cancer patients diagnosed at the age of 40 years or younger at the Cancer Institute Hospital (Tokyo, Japan). Tumor specimens were examined for Helicobacter pylori infection, Epstein-Barr virus positivity, and for the expression of mismatch repair genes to indicate microsatellite instability.
| INTRODUC TI ON
Gastric cancer (GC) is the third most frequent cause of cancerrelated deaths worldwide. 1 The incidence of GC increases after the age of 50 years and peaks in the 60s to 70s. [2] [3] [4] [5] [6] Aging is one of the major factors for GC, like other cancers, yet a substantial subgroup of GCs occurs in younger individuals; this cohort is referred to as GC in young adults (GCYA). 2, 7 A number of studies on GCYA report their universal clinicopathological features, an equal gender distribution, advanced disease with poor outcome, and diffuse-type dominant histology. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Whether there are common backgrounds explaining the early onset of GC awaits investigation. Whether GCYAs reveal higher malignant potential is also unclear, as a recent study reported that prognosis does not differ from the general population when patients were grouped by their clinical stage. 13, 14 Treatment of GCYA is presently based on standardized up-to-date approaches established for GC in general.
The comprehensive molecular analyses of GC, including The
Cancer Genome Atlas (TCGA), suggested 4 molecular subtypes: tumors positive for Epstein-Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and chromosomal instability (CIN).
Among these subtypes, GS subtype tumors tend to reveal relatively early onset and diffuse-type histology, 19 suggesting that the molecular background of GCYA might relate to the GS subtype. In line with this possibility, a recent molecular analysis of GCYA reported that approximately two-thirds of GCYA can be classified into the GS subtype. 20 Gastric cancers with the GS subtype are barely sensitive to molecular-targeted drugs, as they have few actionable alterations such as driver gene mutations or receptor tyrosine kinase (RTK) amplifications. Only 11% of GCYA tumors are positive for EBV or MSIhigh, the patient of which would benefit from immune checkpoint inhibitors. 19 It is therefore crucial to investigate the molecular traits of GCYA to obtain a clue to explore therapeutic strategies.
In the present study, we studied a substantial number of GCYA cases encountered in the Cancer Institute Hospital (Tokyo, Japan)
for their clinicopathological features and molecular characteristics.
Our work identifies an enrichment of a fusion gene in the cohort that potentially plays a pathological role in GCYA patients.
| MATERIAL S AND ME THODS

| Patients and data collection
This study was retrospectively undertaken at the Cancer Institute 
| Tissue microarray assembly
Representative tumor areas were defined on H&E stained slides and corresponding tissue from surgical specimens were obtained and assembled on tissue microarray. These were used to examine gene splitting and fusion by FISH and to test positivity of MSI by immunohistochemistry (IHC). The MSI status was also examined using formalin-fixed paraffin-embedded (FFPE) specimens.
| Evaluation of HP infection status
Helicobacter pylori infection status was examined through the follow- younger age-onset gastric cancers, and its presence could contribute to their aggressive characteristics.
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| Evaluation for EBV and MSI
| Reverse transcription-PCR and DNA sequencing
Total RNA was extracted from FFPE specimens using the Recover All Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific, Waltham, MA, USA). The extracted RNAs were processed for RT using specific primer (5′-GAAGCCAATGCTCCAACT-3′) and for PCR with DNA polymerase named PlatinumTaq High Fidelity (Thermo Fisher Scientific). Resulting PCR fragments were subcloned and sequenced using following primers: 5′-TTGGGTCCAACACCAAAAAC-3′ (forward) and 5′-GAAGCCAATGCTGTCCAACT-3′ (reverse).
| RNA sequencing
Total RNA was extracted from frozen tissue by RNeasy Micro kit (Qiagen, Venlo, The Netherlands) and its quality was assessed with JGCA, Japanese Gastric Cancer Association; LN, lymph node; m, mucosa; mp, muscularis propria; se, tumor penetration of serosa; si, tumor invasion of adjacent structures; sm, submucosa; ss, subserosa. Patients who were alive at this cut-off date were treated to be censored.
| Statistical analyses
Overall survival was calculated from the date of surgery to death of any cause. The statistical differences of survival curves were assessed by log-rank test, and cases where P < .05 were considered to be significant.
All statistical analyses were carried out using GraphPad Prism version 7.03 for Windows (GraphPad Software, San Diego, CA, USA).
| RE SULTS
| Patient characteristics
From January 2006 to September 2015, a total of 4809 patients with gastric adenocarcinoma underwent gastrectomy in our hospital. Among them, 178 patients (3.7%) were grouped as GCYA but 32 patients were excluded from the analysis due to insufficient access to their sample.
Ultimately, 146 patients were enrolled to the present study ( Table 1 ).
The clinicopathological features of our cohort (women, 51.4%; diffuse type, 93.2%) was consistent with previous reports on GCYA.
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| Helicobacter pylori infection
Among 146 GCYA patients, 45 patients (30.8%) were positive for HP infection, examined by elevated anti-HP Ab levels (IgG) (>3 U/mL), positive for the urea breath test (>2.5‰), history of eradication therapy, and direct inspection of bacteria in the FFPE specimen stained by H&E and anti-HP Ab. In addition, 86 patients (58.9%) revealed stomach mucosa with chronic inflammation, which is highly suggestive of HP infection. Among the remaining 15 patients, 7 patients were judged to be possibly HP-negative but could not by evaluated sufficiently. Eight patients (5.8%) were judged to be HP-negative, and 4 of them had tumors located at the esophagogastric junction or gastric cardia. These results indicate that inflammatory stomach mucosa causally related to HP infection is a strong background of GCYA ( Figure 1 ).
| Molecular profiling of GCYA
Comprehensive molecular analyses of GCs 19, 26 have led to molecularbased classifications and offered specific and effective treatment options. Both EBV and MSI tumors are often sensitive to immunotherapy, 27, 28 and thus have come to form independent entities among GCs. 29 To investigate the molecular profile of GCYA, we first exam- To illustrate the distinctive features of GCYAs, we compared the histological classification and molecular subtypes with TCGA cohort ( Figure 4A ). Consistent with previous reports, 20 our GCYA cohort was characterized by diffuse-type histology, GS subtype predominant, and few MSI tumor. The detailed clinical, pathological, and molecular profile for each case is summarized in Figure 4B .
The rearrangement of ALK, RET, ROS1, and NTRK1 are known to be driver fusions in lung cancer, 30 and FISH analysis is a versatile method to screen for those fusions. 31 found 22 cases that were positive for CLDN18-ARHGAP. This comprises 15.1% of our analysis, which is a major subgroup in our GCYA cohort ( Figure 4B ).
| Characterization of CLDN18-ARHGAP fusion
The fusion genes between CLDN18 and ARHGAP26 reported in TCGA were found between exon 5 of CLDN18 and either exon 10 or 12 of ARHGAP26. 19 The majority of the fusions occurred between exon 12, which we called variant 1 (and the other variant 2). To identify the nature of fusion genes found in our cohort, we extracted RNA from the FFPE specimens and their cDNA was sequenced for 18 cases positive for CLDN18-ARHGAP26 fusion in the FISH analysis ( Figure 6 ). Among them, 12 revealed either variant 1 (n = 11) or variant 2 (n = 1). Interestingly, in 6 cases, both of these types were detected, indicating heterogeneous origin of the fusion gene. In 2 cases of CLDN18-ARHGAP6, the breakpoint was identical to that reported in TCGA cohort (exon 2 of ARHGAP6). 19 Furthermore, we could find unprecedented types of fusion of CLDN18 with ARHGAP, namely ARHGAP10 (exon 8) or ARHGAP42 (exon 7). All of these ARHGAP genes were found to be fused to CLDN18 in an in-frame manner, implying an expression of chimeric protein with the GAP activity is preserved among these ARHGAP subtypes.
| Clinical relevance of CLDN18-ARHGAP
To address the significance of the CLDN18-ARHGAP fusion gene, we compared clinicopathological features between fusion-positive and -negative cases. As summarized in Table 2 , we found no statistically significant differences for gender, tumor location, histological type, gross appearance, or invasion depth of tumors between positives and negatives. However, patients with CLDN18-ARHGAP fusion were diagnosed at earlier an age than those without ( Figure 7A Table 2 ). We did not find any clinicopathological features that specify the newfound fusions, CLDN18-ARHGAP10 and CLDN18-ARHGAP42 (n = 2) from previously known fusions (n = 20; data not shown).
A Kaplan-Meier analysis indicated that cases with the CLDN18-ARHGAP fusion gene showed worse prognosis than those without (P < .001). The median follow-up of patients who survived was 75.3 months (95% confidence interval, 70.0-80.7) and 34 patients (23.3%) died by the cut-off date. Importantly, when 24 patients diagnosed with stage IV disease were grouped, the OS rate turned out to be significantly different between the positives and negatives (P = .004) ( Figure 7C ).
To further address whether the age factor might affect the relevance of the fusion, we grouped our GCYA cohort into younger and older populations by median age. Interestingly, in 22 CLDN18-ARHGAP fusion-positive cases the OS rate was lower in younger patients (n = 11) than in older (n = 11), whereas in 124 fusion-negative cases age revealed little effect on survival (Figure 8 ).
| D ISCUSS I ON
In our GCYA cohort, however, approximately 95% of patients were indicative for HP infection, which is the major environmental factor associated with tumorigenesis of GC, and classified as a class I TA B L E 2 Characteristics of CLDN18-ARHGAP-positive and -negative tumors in patients with gastric cancer Patients with fusion had more association with large tumor, metastatic lymph nodes (LNs), and advanced stage. JGCA, Japanese Gastric Cancer Association m, mucosa; mp, muscularis propria; se, tumor penetration of serosa; si, tumor invasion of adjacent structures; sm, submucosa; ss, subserosa. 
P=0.004
F I G U R E 8 Impact of CLDN18-ARHGAP fusion in younger age groups. CLDN18-ARHGAP-positive and -negative patients of our cohort were grouped into younger and older subgroups by the median age. Note that in CLDN18-ARHGAP fusionpositive cases the overall survival rate was lower in younger patients than in older, whereas in fusion-negative cases age revealed little effect on survival carcinogen by WHO. 32 Among these cases, 28 patients (19.2%) experienced peptic ulcer in the past, suggesting the history of severe HP infection. This implies that HP infection must also have a significant impact on the younger-age onset, 33 and that the genomic alterations toward carcinogenesis in GCYA could follow a process similar to that of the general GC population.
Cancers in young patients are often associated with inherited risk factors, as exemplified in Lynch syndrome 34 or hereditary breast and ovarian cancer. 35 The vast majority of GC arises sporadically, and GC linked to hereditary diffuse-type GC or familial intestinal GC is rare (<3%). 32, 36 Although a germline mutation analysis is required to assess the inherited factors, there was no remarkable family history for cancer or GC in our GCYA population, discounting the possibility that inherited factors are involved. 37, 38 claudin protein family member expressed specifically in stomach epithelial cells and has essential functions in tight junctions. [44] [45] [46] There is a transmembrane domain at its amino-terminus which locates CLDN18 to the plasma membrane, and the carboxyl-terminal domain is known to interact with actin regulatory proteins such as cadherin, integrin, and RhoA. 47 Thus, claudin lacking the carboxylterminal domain could disconnect all the actin regulatory proteins from the junctional complex and loosen cell-to-cell and/or cell-tomatrix connections.
The Rho-GTPase activity of ARHGAP converts active RhoA to the inactive form. 48 The existence of multiple patterns for ARHGAP that we and others have found strongly suggests that this fusion protein acquires a pathological role by recruiting GAP activity to CLDN18. 49, 50 Thus, the activity of Rho-GAP of ARHGAP26 will be ectopically enriched in the vicinity of the plasma membrane by virtue of CLDN18, and constitutively inhibit the RhoA activity at that site. 19, 49, 50 As a constitutive inactive mutation of RhoA relates to the acquisition of oncogenic phenotype, 48 this ectopic activity of ARHGAP26 must be involved in its pathogenicity.
Similar to other known fusions, the newfound CLDN18-ARHGAP10 and CLDN18-ARHGAP42 contained the catalytic RhoGAP domain. These new fusions were different from the others in that both also contained an intact PH domain. Although the relevance of the PH domain has been discussed, 49 we consider it more likely that it is dispensable for the pathogenicity of the CLDN18-ARHGAP fusion gene, given the small number of cases that contained the domain.
Therefore, in a worst scenario, both continuous RhoA inactivation and disruption of the junctional complex might take place simultaneously in the presence of the CLDN18-ARHGAP fusion protein, contributing to the diffuse property of the tumors. Supporting this hypothesis, overexpression of CLDN18-ARHGAP promoted cell motility in vitro. 49 It will be interesting to address how its expression would affect cellular proliferation and if the fusion protein is druggable.
In conclusion, GCYAs arise based on the chronic inflammation of gastric mucosa, typically in association with HP infection, similarly to GC in older age groups. Among the characteristics of GCYA shared with the GS subtype, formation of the CLDN18-ARHGAP fusion gene reveals a remarkable genetic feature, which might contribute to the aggressive nature of GC in younger patients.
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